Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study
{{output}}
Background: Satralizumab, an interleukin-6 receptor monoclonal antibody, is an established therapy for neuromyelitis optica spectrum disorder (NMOSD). While randomized trials have demonstrated their efficacy and short-term safety... ...
